TET vs. ZTF, SYNT, ESNT, ELM, VCT, KMR, SOLG, FXPO, GGP, and GFM
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Zotefoams (ZTF), Synthomer (SYNT), Essentra (ESNT), Elementis (ELM), Victrex (VCT), Kenmare Resources (KMR), SolGold (SOLG), Ferrexpo (FXPO), Greatland Gold (GGP), and Griffin Mining (GFM). These companies are all part of the "basic materials" sector.
Zotefoams (LON:ZTF) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
75.1% of Zotefoams shares are held by institutional investors. Comparatively, 70.1% of Treatt shares are held by institutional investors. 18.7% of Zotefoams shares are held by insiders. Comparatively, 12.3% of Treatt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Treatt has higher revenue and earnings than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.
Zotefoams received 87 more outperform votes than Treatt when rated by MarketBeat users. Likewise, 69.49% of users gave Zotefoams an outperform vote while only 68.83% of users gave Treatt an outperform vote.
In the previous week, Zotefoams and Zotefoams both had 1 articles in the media. Treatt's average media sentiment score of 0.00 equaled Zotefoams'average media sentiment score.
Zotefoams pays an annual dividend of GBX 7 per share and has a dividend yield of 1.8%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.7%. Zotefoams pays out 3,684.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zotefoams is clearly the better dividend stock, given its higher yield and lower payout ratio.
Treatt has a net margin of 7.42% compared to Treatt's net margin of 7.28%. Treatt's return on equity of 8.20% beat Zotefoams' return on equity.
Treatt has a consensus target price of GBX 655, indicating a potential upside of 39.81%. Given Zotefoams' higher possible upside, analysts clearly believe Treatt is more favorable than Zotefoams.
Zotefoams has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Treatt has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
Summary
Zotefoams beats Treatt on 9 of the 17 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools